RESUMO
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin-mimetic agents that are effective adjuncts in the treatment of diabetes. This class of medications is also associated with promoting weight loss and a low risk of hypoglycemia, and some have been shown to be associated with a significant reduction of major cardiovascular events. Mounting evidence suggests that GLP-1 RAs have benefits beyond reducing blood glucose that include improving kidney function in people living with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), a common microvascular complication of T2DM. Several large clinical studies, the majority of which are cardiovascular outcome trials, indicate that GLP-1 RA therapy is safe and tolerable for people living with T2DM and compromised renal function, and also suggest that GLP-1 RAs may have renoprotective properties. Although evidence from clinical trials has shown GLP-1 RAs to be safe and efficacious in people living with T2DM and renal impairment, their use is uncommon in this patient population. With continuing developments in the field of GLP-1 RA therapy, it is important for physicians to understand the benefits and practical use of GLP-1 RAs, as well as the clinical evidence, in order to achieve positive patient outcomes. Here, we review evidence on GLP-1 RA use in people living with T2DM and CKD and summarize renal outcomes from clinical studies. We provide practical considerations for GLP-1 RA use to provide an added benefit to guide treatment in this high-risk patient population.
Type 2 diabetes mellitus (T2DM) is a common disorder characterized by insulin resistance and dysfunction of insulin-producing beta cells of the pancreas. People living with T2DM have an increased risk of developing complications, including chronic kidney disease (CKD), which itself is associated with increased mortality. Both the American Diabetes Association and Kidney Disease Improving Global Outcomes organization provide updated pharmacological recommendations for treating T2DM in people with CKD that include the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). GLP-1 RAs are effective and safe treatments for controlling blood sugar levels and reducing body weight, and evidence from large clinical trials also suggests that GLP-1 RAs may be renoprotective. Despite the benefits of GLP-1 RAs, they are not commonly prescribed in people living with T2DM and CKD. Healthcare practitioners need to be aware of the most recent information so that they can make informed decisions when selecting treatment options. The objective of this review is to summarize the main renal outcomes from clinical studies while providing practical guidance on the use of GLP-1 RAs.
RESUMO
Diabetes and frailty are two conditions that frequently occur concurrently and are increasingly prevalent in the older patient. We review the concept, epidemiology and consequences of frailty, and the implications of the presence of frailty in the management of diabetes. Frailty is associated with decreased quality of life, a risk of falls, new or increased disability, hospitalization, and increased mortality. All of these factors affect the management of diabetes in older patients. It is important to rule out frailty in all diabetic patients aged >70 years; if frailty is suspected, a comprehensive and multidisciplinary medical and functional assessment of the patient should be conducted to develop an individualized treatment plan. This plan should include nutritional measures, physical activity, and education on self-care and diabetes; drugs should not be used without a clear indication. Antihyperglycemic drugs that may cause excessive weight loss and/or are associated with a high risk of hypoglycemia should be avoided.
Assuntos
Diabetes Mellitus/epidemiologia , Fadiga/epidemiologia , Idoso Fragilizado , Debilidade Muscular/epidemiologia , Magreza/epidemiologia , Idoso , Terapia Combinada , Comorbidade , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/fisiopatologia , Diabetes Mellitus/terapia , Fadiga/etiologia , Feminino , Humanos , Hipoglicemiantes/efeitos adversos , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/diagnóstico , Educação de Pacientes como Assunto , Exame Físico , Psicologia , Qualidade de Vida , Risco , Autocuidado , Magreza/etiologia , Redução de Peso/efeitos dos fármacosRESUMO
BACKGROUND AND AIM: This paper presents results from the Spanish subpopulation of a study comparing Conversation Maps™ (CM)-based education with regular care (RC) in type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: Adult patients with T2DM who were considered as not demonstrating ideal disease management were randomly assigned to CM or RC with assessments following (Visit 2), and at follow-up 6 months after (Visit 3), the final CM session. The primary endpoint was diabetes knowledge at Visit 3. RESULTS: 310 patients were randomised to receive CM education (n=148) or RC (n=162). Median knowledge scores were ranked significantly higher in the CM group than the RC group at Visit 2 and Visit 3 (p<0.001). No significant differences in clinical and other outcomes were identified between the interventions, except satisfaction with care (p<0.001, Visit 2; p=0.055, Visit 3) and perception of goal attainment (p<0.001 and p = 0.046, respectively) that were both higher in the CM group. CONCLUSIONS: In these patients from Spain, CM was superior to RC in terms of diabetes knowledge 6 months after education was completed, suggesting that CM should be considered for use in patients requiring diabetes education.
Assuntos
Recursos Audiovisuais , Diabetes Mellitus Tipo 2/psicologia , Educação de Pacientes como Assunto/métodos , Adulto , Idoso , Diabetes Mellitus Tipo 2/terapia , Processos Grupais , Educadores em Saúde/psicologia , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Pessoa de Meia-Idade , Enfermeiras e Enfermeiros/psicologia , Participação do Paciente , Satisfação do Paciente , Médicos de Família/psicologia , Relações Profissional-Paciente , EspanhaRESUMO
Diabetes and frailty are two conditions that frequently occur concurrently and are increasingly prevalent in the older patient. We review the concept, epidemiology and consequences of frailty, and the implications of the presence of frailty in the management of diabetes. Frailty is associated with decreased quality of life, a risk of falls, new or increased disability, hospitalization, and increased mortality. All of these factors affect the management of diabetes in older patients. It is important to rule out frailty in all diabetic patients aged >70 years; if frailty is suspected, a comprehensive and multidisciplinary medical and functional assessment of the patient should be conducted to develop an individualized treatment plan. This plan should include nutritional measures, physical activity, and education on self-care and diabetes; drugs should not be used without a clear indication. Antihyperglycemic drugs that may cause excessive weight loss and/or are associated with a high risk of hypoglycemia should be avoided (AU)
La diabetes y la fragilidad son 2 procesos que se producen a menudo simultáneamente y son cada vez más prevalentes en los pacientes mayores. Revisamos aquí el concepto, la epidemiología y las consecuencias de la fragilidad, y las implicaciones de la presencia de fragilidad en el tratamiento de la diabetes. La fragilidad se asocia con un empeoramiento de la calidad de vida, riesgo de caídas, aparición o aumento de la discapacidad, hospitalización y aumento de la mortalidad. Todos estos factores afectan al tratamiento de la diabetes en los pacientes de mayor edad. Es importante descartar la existencia de fragilidad en todos los pacientes diabéticos de más de 70 años de edad; si se sospecha fragilidad, debe efectuarse una valoración médica y funcional, exhaustiva y multidisciplinaria, del paciente para idear un plan de tratamiento individualizado. Este plan debe incluir medidas nutricionales, actividad física y educación sobre los cuidados personales y la diabetes; no deben utilizarse fármacos si no están claramente indicados. Deben evitarse los hipoglucemiantes que puedan causar una pérdida de peso excesiva o que se asocien con un riesgo elevado de hipoglucemia (AU)
Assuntos
Humanos , Diabetes Mellitus/epidemiologia , Sarcopenia/epidemiologia , Envelhecimento , Hiperglicemia/epidemiologia , Idoso Fragilizado/estatística & dados numéricos , Qualidade de Vida , Perfil de Impacto da Doença , Exercício Físico/fisiologia , Terapia NutricionalRESUMO
ANTECEDENTES Y OBJETIVO: Este artículo presenta los resultados de la subpoblación española de un estudio que compara una formación usando Mapas de Conversaciones (TM) (MC) con la atención habitual (AH) en pacientes con diabetes mellitus tipo 2. PACIENTES Y MÉTODOS: A pacientes adultos con diabetes mellitus tipo 2 que se consideró que no tenían un manejo ideal de su enfermedad se les asignó aleatoriamente a recibir MC o AH, realizando una evaluación inmediatamente después (visita 2) y otra a los 6 meses (visita 3) de la sesión final de los MC. La variable principal de valoración fue el conocimiento adquirido sobre la diabetes en la visita 3. RESULTADOS: Participaron 310 pacientes a los que se asignó aleatoriamente a recibir una formación con MC (n = 148) o AH (n = 162). La mediana de la puntuación de conocimiento fue significativamente más elevada en el grupo MC que en el grupo AH tanto en la visita 2 como en la visita 3. No se identificaron diferencias significativas en las variables clínicas o de otra índole entre intervenciones, excepto en la satisfacción con el cuidado (visita 2, p < 0,001; visita 3, p = 0,055) y la percepción de consecución del objetivo (p < 0,001 y p = 0,046 respectivamente) que fueron ambas más elevadas en el grupo MC. CONCLUSIONES: En estos pacientes españoles, los MC fueron superiores a la AH en términos del conocimiento sobre la diabetes 6 meses después de completar la formación, por lo que los MC podrían ser una herramienta a considerar en pacientes que requieran una educación diabetológica
BACKGROUND AND AIM: This paper presents results from the Spanish subpopulation of a study comparing Conversation Maps (TM) (CM)-based education with regular care (RC) in type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: Adult patients with T2DM who were considered as not demonstrating ideal disease management were randomly assigned to CM or RC with assessments following (Visit 2), and at follow-up 6 months after (Visit 3), the final CM session. The primary endpoint was diabetes knowledge at Visit 3. RESULTS: 310 patients were randomised to receive CM education (n=148) or RC (n=162). Median knowledge scores were ranked significantly higher in the CM group than the RC group at Visit 2 and Visit 3 (p < 0.001). No significant differences in clinical and other outcomes were identified between the interventions, except satisfaction with care (p < 0.001, Visit 2; p = 0.055, Visit 3) and perception of goal attainment (p < 0.001 and p = 0.046, respectively) that were both higher in the CM group. CONCLUSIONS: In these patients from Spain, CM was superior to RC in terms of diabetes knowledge 6 months after education was completed, suggesting that CM should be considered for use in patients requiring diabetes education